SCHEMBL13221167

SCHEMBL13221167

Cc1cc(Nc2nc(NCCc3ccccc3)cc3nccn23)n[nH]1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IGF1R P08069 3/20 0.44
▸ FGFR1 P11362 3/20 0.44
▸ KDR P35968 3/20 0.44
▸ AURKA O14965 3/20 0.44
▸ PAK4 O96013 2/20 0.44
▸ AURKB Q96GD4 2/20 0.44
▸ MAPK8 P45983 2/20 0.44
▸ JAK2 O60674 2/20 0.44
▸ DAPK3 O43293 1/20 0.44
▸ ABL1 P00519 1/20 0.44
▸ LCK P06239 1/20 0.44
▸ FYN P06241 1/20 0.44
▸ CSF1R P07333 1/20 0.44
▸ RET P07949 1/20 0.44
▸ PDGFRB P09619 1/20 0.44
▸ FLT1 P17948 1/20 0.44
▸ LTK P29376 1/20 0.44
▸ FLT3 P36888 1/20 0.44
▸ MAPK9 P45984 1/20 0.44
▸ GSK3A P49840 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13221173 0.94 IGF1R (0.43) IGF1RFGFR1KDRAURKAPAK4
SCHEMBL13221166 0.90 PLK4 (0.42) IGF1RFGFR1KDRAURKAPAK4
SCHEMBL13221163 0.90 PLK4 (0.44) IGF1RFGFR1KDRAURKAPAK4
SCHEMBL13221162 0.87 PAK4 (0.43) IGF1RFGFR1KDRAURKAPAK4
SCHEMBL13221177 0.86 AURKA (0.52) IGF1RFGFR1KDRAURKAPAK4
SCHEMBL13221183 0.82 ITK (0.37) IGF1RFGFR1KDRAURKAPAK4
SCHEMBL13221184 0.82 IGF1R (0.54) IGF1RFGFR1KDRAURKAPAK4
SCHEMBL13221178 0.82 CYP2D6 (0.44) IGF1RFGFR1KDRAURKAPAK4
SCHEMBL13221176 0.82 CYP2D6 (0.44) IGF1RFGFR1KDRAURKAPAK4
SCHEMBL13221153 0.81 IGF1R (0.39) IGF1RFGFR1KDRAURKAPAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288536-B2 Kinase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-16 — — US disclosed
US-8288536-B2 Kinase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-16 — — US disclosed
US-20100216765-A1 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-26 — — US disclosed
US-20100216765-A1 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-26 — — US disclosed
US-7713973-B2 Kinase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-11 — — US disclosed
US-7713973-B2 Kinase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216765-A1 KINASE INHIBITORS MAP3K20, MAP3K19, MAP3K1 IGF1R 787/4885FGFR1 610/4885KDR 492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback